Analysis Immunoassay of Anti-Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Antibody by KinExA (CAT#: STEM-MB-0082-CJ)

Introduction

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in the regulation of cholesterol homeostasis.Proprotein conversion ase subtilisin/kexin type 9 (PCSK9) regulates serum LDL cholesterol (LDL-C) by interacting with LDL receptors (LDLR) and is an attractive therapeutic target for lowering LDL-C. By binding to liver low-density lipoprotein (LDL) receptors and promoting their lysosome degradation, PCSK9 reduces LDL uptake and leads to an increase in LDL cholesterol concentration. In vitro, mAb1 inhibits PCSK9 binding to LDLR and attenuates PCSk9-mediated reduction of LDLR protein levels, thereby increasing LDL uptake. Anti-pcsk9 antibody may be an effective treatment for hypercholesterolemia. Inhibition of PCSK9 holds considerable promise as a treatment option for reducing the risk of cardiovascular disease.

Add to Cart Please Inquire

Principle Applications Procedure Materials Notes Related Products

Principle

KinExA is a two-stage analysis system. In the first stage, a number of solutions are prepared, where one partner remains constant (constant binding partner, or CBP) and the other (titrant) is variable, usually serially diluted. As the titrant is added, the free CBP decreases and is analysed by a sophisticated and precise microfluorescence measurement device. The signal generated can be mathematically related to the affinity (KD) of the two molecules for each other, as well as the kinetic parameters of binding (kon) and dissociation (koff).

Applications

Immunology/Inflammation;Pharmacology

Procedure

1. preparation of the functionalized beads which will capture the analyte for measuremen.
2. preparation of a series of solutions consisting of a constant initial concentration of one component of the binary reaction and serial dilutions of the other reactant. The component that is kept constant is the constant binding partner (CBP) , and is the one which will be analyzed.
3. each reaction mixture is sampled and the fluorescence of free CBP bound to the capture beads is obtained for subsequent numerical analysis.

Materials

• Sample Type: Serum, Plasma, Urine
• Equipment: Kinetic Exclusion Assay (KinExA)

Other recommended products

Analysis Affinity of Human Anti-human Interleukin 13 (IL13) Monoclonal Antibodies to IL13 by Kinetic. (CAT#: STEM-MB-0004-CJ)
Analysis Affinity of CD19 to Whole Blood B Cell by KinExA (CAT#: STEM-MB-0048-CJ)
Analysis Immunoassay of Carcinoembryonic Antigen (CEA) by KinExA (CAT#: STEM-MB-0076-CJ)
Analysis Affinity and Kinetics of BoNT/A1 and BoNT/B2 by KinExA (CAT#: STEM-MB-0055-CJ)
Analysis Affinity of HIV-1 Inhibitory Peptide T20 with gp41 N-HR by KinExA (CAT#: STEM-MB-0007-CJ)
Analysis Affinity of 504B3 for LPA species by KinExA (CAT#: STEM-MB-0035-CJ)
Analysis Affinity of Shingosine-1-Phosphate (S1P) and lysophosphatidic Acid (LPA) by KinExA (CAT#: STEM-MB-0024-CJ)
Analysis Affinity of Pcadherin to P-cadherin and CD3 by KinExA (CAT#: STEM-MB-0051-CJ)